Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | RB1 del |
Gene Variant Detail | |
Relevant Treatment Approaches | HDAC Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
RB1 del | prostate cancer | sensitive | JQ1 | Preclinical | Actionable | In a preclinical study, JQ1 treatment inhibited tumor growth in a syngeneic mouse model of RB1-deficient prostate cancer (PMID: 37014264). | 37014264 | |
RB1 del | prostate cancer | sensitive | JQ1 + unspecified PD-L1 antibody | Preclinical | Actionable | In a preclinical study, the combination of JQ1 and an anti-PD-L1 therapy inhibited tumor growth in a syngeneic mouse model of RB1-deficient prostate cancer (PMID: 37014264). | 37014264 | |
RB1 del | prostate adenocarcinoma | sensitive | Decitabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Dacogen (decitabine) inhibited viability of castration-resistant prostate adenocarcinoma cells with loss of RB1 via knockout in culture and inhibited tumor growth in cell line xenograft models (PMID: 37967200). | 37967200 |